Brief: Advaxis Presents Updated Clinical Data From Ongoing Phase 1/2 Trial Of ADXS-503 In NSCLC And Upcoming Milestones

Ayala Pharmaceuticals

11/01/2022 13:28

Jan 11 (Reuters) - Advaxis Inc  ADXS.PK :
    * ADVAXIS PRESENTS UPDATED CLINICAL DATA FROM ONGOING PHASE
1/2
TRIAL OF ADXS-503 IN NSCLC AND UPCOMING MILESTONES
    * ADVAXIS-OVERALL RESPONSE RATE OF 15.4%, DISEASE CONTROL
RATE OF
46% IN PART B WITH DURABLE CLINICAL BENEFIT IN PATIENTS WITH
PRIOR DISEASE PROGRESSION
    * ADVAXIS - PRELIM DATA SHOW DISEASE CONTROL RATE OF 67% IN
FIRST
3 PATIENTS IN PART C, WITH ADXS-503 BEING DOSED WITH
PEMBROLIZUMAB IN FIRST LINE

Source text for Eikon:  ID:nGNXzBQjv 
Further company coverage:  ADXS.PK 

 ((Reuters.Briefs@thomsonreuters.com;))